With an increasing number of neurological manifestations being reported in patients suffering from COVID-19 infection, the need for therapies to treat those conditions as well as other major CNS disorders has, once again, been highlighted. That may be one of the reasons why investors have turned their attention to the space once again, with several members of the BioWorld Neurological Diseases index enjoying an uptick in their share valuations.
The number of clinical trials initiated each year has continued to grow every year over the last decade, sans a slight decrease in 2013, according to data presented in a webcast facilitated by Applied Clinical Trials.
While med-tech dealmaking in the second quarter of 2020 increased by 27% from the first quarter and is in line with the values disclosed during the same period in 2019, M&A money for the industry has fallen significantly.
Although the FDA suggested in May that it might have trouble meeting PDUFA dates due to the COVID-19 pandemic, the 30 approvals of biologics and drugs handed down in June 2020 is the highest number for a single month in the past five years.
RSS
